ABIOMED (ABMD) Impella Data Shows a Sharp Rebound in April - Jefferies

June 11, 2021 8:03 AM EDT
Get Alerts ABMD Hot Sheet
Price: $324.81 +0.31%

Rating Summary:
    11 Buy, 6 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 11 | New: 19
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Jefferies analyst Raj Denhoy reiterated a Buy rating and $425.00 price target on ABIOMED (NASDAQ: ABMD) noting that his dataset, representing Impella data from ~40% of all US sites, showed a sharp rebound in April.

The analyst stated "Our monthly Impella tracker captures data from ~40% of all US Impella sites. The model addresses panel changes, reporting lags, and imputes missing data to improve predictive ability. The output is a dataset that is highly correlated to US Impella actual results over the past 13 quarters with an r-squared of 0.82 using our full panel approach and 0.86 using our same-store approach. The data shows US Impella growth tracking +53-64% versus +49-50% in consensus."

For an analyst ratings summary and ratings history on ABIOMED click here. For more ratings news on ABIOMED click here.

Shares of ABIOMED closed at $298.13 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Jefferies & Co